A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen to
participate in this study) will receive T-1249 at a dose of 200mg daily in combination with a
background antiretroviral regimen for 96 weeks. Only patients that participated in study
T1249-102 can participate in study T1249-105.